Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2002

View Archived Issues

Celltech receives CDP-870 phase III milestone payment from Pharmacia

Embosphere Microspheres approved for treatment of uterine fibroid

PCL-016 enters phase IIa in acne

GenVec initiates phase I trial of AdPEDF in AMD

eXegenics and IDDS terminate merger agreement

Abbott and MerLion collaborate on natural product-based drug discovery

Photogen to acquire medical imaging assets from Alliance

Gruenenthal presents novel siderophores for delivering antibacterial agents

Phosphodiesterase inhibitors discovered at Ortho-McNeil

Bayer researchers present novel anticytomegalovirus agents

New ciclosporin prodrugs with utility in ocular disorders

Two series of TNF-alpha production inhibitors identified at Sanofi-Synthelabo

Gemin X's Bcl-2 inhibitors are effective proapoptotic and antitumor compounds

New nonanticoagulant heparin derivatives retain antiangiogenic/antitumor activity

CJ-13610: design of an orally active and safe 5-LO inhibitor

Long-acting, oral DPP-IV inhibitor and hypoglycemic agent presented in Shizuoka

Effective agents for nephritis without cardiovascular side effects designed at Tanabe Seiyaku

Potent anti-HIV agents targeting viral protease designed by U.S./Japanese team

Novartis files marketing applications for Prexige

NDA for palonosetron accepted for filing by the FDA

Lilly receives FDA approval for Strattera

Teriparatide approved by the FDA to treat osteoporosis